News and stories
Follow the latest releases and stories from Orion and find links to media contacts, image bank and more.
Stock exchange releases
- 10/28/2026 Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline
- 10/26/2026 Changes in Orion Group’s Executive Team as of 1 January 2027
- 10/20/2026 Inside information: Orion upgrades full-year outlook for 2026
- 10/7/2026 125,000 Orion Corporation A shares converted into B shares
Press releases
- 10/24/2026 Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
- 10/14/2026 Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026
- 10/6/2026 Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market
- 10/5/2026 Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing
Subscribe to releases
Subscribe Orion Corporation's stock exchange and press releases to your e-mail.
Subscribe
Orion Pharma content bank
You can find and download Orion Pharma brand images and assets such as logos in the public content bank.
Visit content bank
Corporate Communications contacts
-
-
Christina Weber-Villumsen
Vice President, Corporate Communications, Brand and Public Affairs -
-
Valtteri Manninen
Communications Business Partner, Global Operations -
-